Metformin monotherapy for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Saenz, Antonio ^a   Fernandez Esteban, Inmaculada ^b   Mataix, Angel ^b   Ausejo Segura, Monica ^c   Roqué i Figuls, Marta ^d   Moher, David ^e  

^a IMSALUD   (Spain)

^b Servicio Madrileno de Salud   (Spain)

^c Servicio de Farmacia Atencion Frimaria   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; DIABETES MELLITUS, TYPE 2; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDIABETIC AGENT; METFORMIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964694678     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002966.pub4     Document Type: Review

References (179)

1. Amador-Licona N, Guizar-Mendoza J, Vargas E, Sanchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Archives of Medical Research 2000;31(6):571-5.
2. Campbell IW, Menzis DG, Chalmers J, McBain AM, Brown IRF. One year comparative trial of metformin and glipizide in Type 2 diabetes mellitus. Diabete et Metabolisme 1994;20:394-400.
3. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetes Medicine 2001;18(10):828-34.
4. Chiasson JL, Nadtich L, for the Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001;24(6):989-94.
5. Wolever TMS, Assif L, Basu T, Chiasson JL, Boctor M, Gerstein HC, et al. Miglitol, an alpha-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutrition Research 2000;20(10):1447-56.
6. Chiasson JL, Nadtich L, for the Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001;24(6):989-94.
7. Wolever TMS, AssiffL, Basu T, Chiasson J-L, Boctor M, Gerstein HC, et al. Miglitol, an alpha-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutrition Research 2000;20(10):1447-56.
8. Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BF. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete et Metabolisme 1989;15(6):420-5.
9. Dalzell GW, Hadden DR. A randomized trial tolbutamide and metformin for persistent severe hyperglycaemia in non insulin dependent diabetes mellitus (NIDDM). Irish Journal of Medical Science 1986;155(9):341-2.
10. Damsbo P, Hermann LS, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. Diabetes Care 1998;21(9):1489-94.
11. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group [see comments]. New England Journal of Medicine 1995;333(9):541-9.
12. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group [see comments]. New England Journal of Medicine 1995;333(9):541-9.
13. Goodman AM. Efficacy and safety of metformin. Results of a multicenter trial. Diabetes 1993;42 (Suppl 1):57.
14. Del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetologica 2003;40(1):20-7.
15. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14(4):342-4.
16. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 1996;19(11):1185-9.
17. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clinical Therapeutics 2003;25(3):890-903.
18. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II. diabetes. Diabetes Care 1996;19(1):64-6.
19. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51(12):3479-85.
20. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51(12):3479-85.
21. Hermann LF, Schersten B, Bitzen PO, Kjellstrom T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17(10):1100-9.
22. Hermann LS, Bitzen PO, Kjellstrom T, Lindgarde F, Schersten B. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. Diabete et Metabolisme 1991;17:201-8.
23. Hermann LS, Kjellstrom T, Nilsson EP. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabete et Metabolisme 1991;17:174-9.
24. Hermann LS, Ranstam J, Vaaler S, Melander A. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obesity and Metabolism 1999;1(4):227-32.
25. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabetic Medicine 1994;11(10):953-60.
26. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II. Study. American Journal of Medicine 1997;103(6):483-90.
27. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II. Study. American Journal of Medicien 1997;103(6):483-90.
28. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23(11):1660-5.
29. Horton ES, Clinkenbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23(11):1660-5.
30. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II. diabetes mellitus [see comments]. New England Journal of Medicine 1998;338(13):867-72.
31. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II. non-insulin-dependent diabetes. Obesity Research 1998;6(1):47-53.
32. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology 2001;37(5):1344-50.
33. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22(1):119-24.
34. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete et Metabolisme 1991;17(1 Pt 2):209-12.
35. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2003;88(4):1637-45.
36. Tamez Pérez HE, Gómez de Ossio MD, Ibarra Martínez IB. Normoglucemia in newly diagnosed no insulin dependent diabetes mellitus. Non pharmacologic therapy vs. pharmacologic therapy [Normoglucemia en diabetes mellitus no dependiente de insulina de reciente diagnóstico. Tratamiento no farmacológico vs. tratamiento farmacológico]. Medicina Interna de Mexico 1997;13(6):272-5.
37. Tamez Pérez HE, Gómez de Ossio MD, Ibarra Martínez IB. Normoglucemia in newly diagnosed no insulin dependent diabetes mellitus. Non pharmacologic therapy vs. pharmacologic therapy [Normoglucemia en diabetes mellitus no dependiente de insulina de reciente diagnóstico. Tratamiento no farmacológico vs. tratamiento farmacológico]. Medicina Interna de Mexico 1997;13(6):272-5.
38. Tessier D, Maheux P, Khalil A, Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism: Clinical and Experimental 1999;48(7):897-903.
39. Teupe B, Bergis K. Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete et Metabolisme 1991;17:213-7.
40. Uehara MH. Metabolic and hemodinanic effects of metformin in patients with type 2 diabetes mellitus and hypertension [Efeitos metabólicos e hemodinâmicos da metformina em pacientes com diabetes mellitus tipo 2 e hipertensäo arterial essencial]. Tesis: Universidae Federal de Säo Paulo. Escola Paulista de Medicina para obtención del grado de Doutor 1999.
41. Uehara MH, Kohlmann NEB, Zanella MT, Ferreira SRG. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obesity and Metabolisme 2001;3(5):319-25.
42. Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352(9131):854-65.
43. Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352(9131):854-65.
44. Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352(9131):854-65.
45. Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352(9131):854-65.
46. Abbasi F, Kamath V, Rizvi AA, Carantoni M, Chen YD, Reaven GM. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients: Evidence for a central role of adipose tissue. Diabetes Care 1997;20:1863-9.
47. Abbink A. No title supplied. No source supplied 2001.
48. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1999;131(3):182-8.
49. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996;19(3):252-4.
50. Bingle JP, James JI. Metformin combined with chlorpropamide in the treatment of Diabetes mellitus. Practitioner 1964;192:567-72.
51. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Research 1992;19(2):69-76.
52. Cairns SA, Shalet S, Marshall AJ, Hartog M. A comparison of phenformin and metformin in the treatment of maturity onset diabetes. Diabete et Metabolisme 1977;3(3):183-8.
53. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, Vara E, Calle JR, Munguira ME, et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabete et Metabolisme 1995;21(4):256-60.
54. Cefalu WT, Schneider DJ, Carlson HE, Migdal P, Gan Lim L, Izon MP, et al. Effect of combination glipizide GITS metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 2002;25(12):2123-8.
55. Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993;16(7):1035-8.
56. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Annals of Internal Medicine 1994;121(12):928-35.
57. Ciaraldi TP, Kong APS, Chu NV, Kim DD, Baxi S, Loviscach M, et al. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 2002;51(1):30-6.
58. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. British Medical Journal 1977;2(6102):1576-8.
59. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1996;81(11):4059-67.
60. De Silva SR, Betteridge DJ, Shawe JE, Cudworth AG, Alberti KG. Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment. Diabete et Metabolisme 1979;5(3):223-9.
61. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clinical Pharmacokinetics 2002;41(15):1301-9.
62. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clinical Therapeutics 2000;22(12):1395-409.
63. Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P, et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetologica 1999;36(1-2):61-5.
64. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clinical Cardiology 2001;24(2):151-8.
65. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. Journal of the American Medical Association 2000;283:1695-702.
66. Fritsche A, Schmulling RM, Haring HU, Stumvoll M. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetologica 2000;37(1):13-8.
67. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II. diabetes: results of a double-blind, placebo-controlled, dose-response trial. American Journal of Medicine 1997;103(6):491-7.
68. Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study. Clinical Therapeutics 2002;24(9):1401-13.
69. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obesity and Metabolism 2002;4(6):368-75.
70. Garber A, Marre M, Blonde L, Allavoine T, Howlett H, Lehert P, et al. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes. Diabetes, Obesity and Metabolism 2003;5(3):171-9.
71. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2003;88(8):3598-604.
72. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D, The Glyburide/Metformin Initial Therapy Study Group. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes, Obesity and Metabolism 2002;4(3):201-8.
73. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy in Type 2 diabetic patients inadequately controlled on metformin. Diabetic Medicine 2002;19(8):673-80.
74. Gardner D, Griffing G, Hamdy O. Triple therapy of metformin, sulfonylurea, and insulin in type II. diabetic. Journal of investigative medicine 1995;43 (Suppl 3):461A.
75. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. European Journal of Clinical Pharmacology 1993;44(2):107-12.
76. Golay A, Guillet-Dauphine N, Fendel A. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabet Metab Rev 1995;11:S63.
77. Gregorio F, Ambrosi F, Angelici F, Cristallini S, Dini FL, Vespasiani G, et al. Effect of metformin on body mass index, blood lactate and plasma glucose in type II. diabetes mellitus. Medicina Rivista de la Enciclopedia Medica Italiana 1989;9(2):200-04.
78. Gregorio F, Ambrosi F, Manfrini S, Velussi M, Carle F, Testa R, et al. Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabetic Medicine 1999;16(12):1016-24.
79. Groop L, Widen E, Franssila KA, Ekstrand A, Saloranta C, Schalin C, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32(8):599-605.
80. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?. Diabete et Metabolisme 1991;17:218-23.
81. Hanefeld M, Bar K. Efficacy and safety of combined treatment of type 2 diabetes with acarbose and metformin. Diabetes und Stoffwechsel 1998;7(5):186-90.
82. Hermann LS, Karlsson JE, Sjostrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. European Journal of Clinical Pharmacology 1991;41(3):263-5.
83. Higginbotham L, Martin FIR. Double-blind trial of metformin in the therapy of non-ketotic diabetics. Medical Journal of Australia 1979;2(3):154-6.
84. Higginbotham L, Martin FIR. Double-blind trial of metformin in the therapy of non-ketotic diabetics. Medical Journal of Australia 1979;2(3):154-6.
85. Hirsch IB. Metformin added to insulin therapy in poorly controlled type 2 diabetes. Diabetes Care 1999;22:854.
86. Holman RR, Steemson J, Turner RC. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabetic Medicine 1987;4(5):457-62.
87. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II. diabetes. Acta Endocrinologica 1989;120(3):257-65.
88. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21(12):2135-39.
89. Johansen K. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin. Diabete et Metabolisme 1984;10(4):219-23.
90. Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II. diabetic patients. Metabolism: Clinical and Experimental 1993;42(9):1217-22.
91. Jones KL Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25(1):89-94.
92. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabetic Medicine 1990;7:510-4.
93. Josse RG. Acarbose for the treatment of Type II. diabetes: The results of a Canadian multi-centre trial. Diabetes Research and Clinical Practice 1995;28:S167-72.
94. Kirk JK, Pearce KA, Michielutte R, Summerson JH. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?. Journal of Family Practice 1999;48(11):879-82.
95. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diabete et Metabolisme 1991;17(1 Pt 2):235-40.
96. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346(6):393-403.
97. Lalor BC, Bhatnagar D, Winocour PH, Ishola M, Arrol S, Brading M, et al. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabetic Medicine 1990;7:242-5.
98. Leblanc H, Marre M, Billault B, Passa P. Value of combined subcutaneous infusion of insulin and metformin in 10 insulin-dependent obese diabetics. Diabete et Metabolisme 1987;13(6):613-7.
99. Lim P, Khoo OT. Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus. Medical Journal of Australia 1970;1(6):271-3.
100. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II. diabetes mellitus. Diabetologia 1999;42(4):406-12.
101. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete et Metabolisme 1994;20(1):15-9.
102. McAlpine LG, McAlpine CH, Waclawski ER, Storer AM, Kay JW, Frier BM. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. European Journal of Clinical Pharmacology 1988;34(2):129-32.
103. Molitch ME, Fujimoto W, Hamman RF, Knowler WC, Diabetes Prevention Program Research Group. The diabetes prevention program and its global implications. Journal of the American Society of Nephrology 2003;14 (Suppl 2)(7):S103-7.
104. Munk, W. Treatment of obese diabetic patients using glucophage retard. Zeitschrift für Allgemeinmedizin 1975;51(14):681-3.
105. Nagi DK, Mohamed A, V, Yudkin JS. Effect of metformin on intact proinsulin and des 31, 32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabetic Medicine 1996;13:753-7.
106. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16(4):621-9.
107. Niazi R, Muzaffar Z. Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II. (NIDDM) patients. Journal of the Pakistan Medical Association 1998;48(11):336-8.
108. Ohmura C, Tanaka Y, Mitsuhashi N, Atsum Y, Matsuoka K, Onuma T, et al. Efficacy of low-dose metformin in Japanese patients with type 2 diabetes mellitus. Current Therapeutic Research Clinical and Experimental 1998;59:889-95.
109. Ohnhaus EE, Berger W, Duckert F, Oesch F. The influence of Dimethylbiguanide on Phenprocoumon elimination and its mode of action. Klinische Wochenschrift 1983;61:851-8.
110. Pedersen O, Nielsen O, Bak J, Richelsen B, Beck NH, Sorensen N. The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. Diabetic Medicine 1989;6(3):249-56.
111. Ponssen HH, Elte JW, Lehert P, Schouten JP, Bets D. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clinical Therapeutics 2000;22(6):709-18.
112. Prager R, Schernthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II. diabetics. Diabetes 1983;32(12):1083.
113. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete et Metabolisme 1986;12(6):346-50.
114. Elkeles RS. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM). Diabete et Metabolisme 1991;17(1 Pt 2):197-200.
115. Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Medicine 1988;5(7):653-8.
116. Rains SG, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. Journal of the Royal Society of Medicine 1989;82(2):93-4.
117. Raptis AE, Tountas NB, Yalouris AG, Halvatsiotis PG, Raptis SA. Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients. Hormone and Metabolic Research 1996;28(2):89-4.
118. Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial. Diabetic Medicine 1998;15(12):997-1002.
119. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21(5):701-5.
120. Rodger NW, Chiasson JL, Josse RG, Hunt JA, Palmason C, Ross SA, et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clinical and Investigative Medicine/Medecine Clinique et Experimentale 1995;18(4):318-24.
121. Scarpello J, Hodgson E, Howlett H. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabetic Medicine 1998;15:651-6.
122. Schneider J, Erren T, Zofel P, Kaffarnik H. Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus. Atherosclerosis 1990;82(1-2):97-103.
123. Schneider J. Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. Diabete et Metabolisme 1991;17(1 Pt 2):185-90.
124. Sivitz WI, Wayson SM, Bayless ML, Larson LF, Sinkey C, Bar RS, et al. Leptin and body fat in type 2 diabetes and monodrug therapy. Journal of Clinical Endocrinology and Metabolism 2003;88(4):1543-53.
125. Sotaniemi EA, Vierimaa E, Huupponen R, Karvonen I, Vuoti MJ, Rytomaa K. Insulin and sulphonylurea in the therapy of type 2 diabetes. Diabetes Research and Clinical Practice 1990;8(3):243-51.
126. Sundaresan P, Lykos D, Daher A, Diamond T, Morris R, Howes LG. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care 1997;20:692-7.
127. Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Research in Clinical Practice 2003;59(1):43-9.
128. Tessari P, Biolo G, Bruttomesso D, Inchiostro S, Panebianco G, Vedovato M, et al. Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 1994;79:1553-60.
129. Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism 2003;52(7):862-7.
130. Trischitta V, Italia S, Mazzarino S, Buscema M, Rabuazzo AM, Sangiorgio L, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992;15(4):539-42.
131. Trischitta V, Italia S, Raimondo M, Guardabasso V, Licciardello C, Runello F, et al. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?. Journal of Endocrinological Investigation 1998;21(11):744-7.
132. Van der Waal P, Scheen A, vanGaal L, Schmitt H, Heine R, and the SWIM Study Group. Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents. Diabetes 1996;45 (Suppl 2):286A.
133. Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA, Squatrito S. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete et Metabolisme 1991;17(1 Pt 2):232-4.
134. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study. Diabetic Medicine 1999;16(9):755-61.
135. Wilson JA, Scott MM, Gray RS. A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes. Hormone and Metabolic Research 1989;21(6):317-9.
136. Yale JF. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2001;134(9 Pt 1):737-45.
137. Yki JH, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Annals of Internal Medicine 1999;130(5):389-96.
138. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999;48(12):2414-21.
139. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
140. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 1999. Diabetes Care 1999;22 (Suppl 1):S1-114.
141. Metformin Hydrochloride. American Hospital Formulary Service Drug Information. Bethesda, USA: American Society of Health-System Pharmacists, Inc., 1999:2755-63.
142. Bailey CJ, Turner RC. Drug Therapy: Metformin. New England Journal of Medicine 1996;334:574-9.
143. Begg CB, Mazundar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
144. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering Agent: a meta-analysis. Diabetes-Metabolism Reviews 1995;11 (Suppl 1):S57-62.
145. Chiasson JL, Nadtich L, Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001;24(6):989-94.
146. The Cochrane Collaboration. The Cochrane Library [database on disk and CDROM]. Oxford: Update Software; 2000. Updated quaterly, 2000.
147. Cochrane Menstrual Disorders and Subfertility Group. Statistical guidelines for reviewers. The Cochrane Collaboration. Database on CD-ROM and internet 2000, Issue 2.
148. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Statistics in Medicine 1989;8:441-54.
149. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 1999;131(4):281-303.
150. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
151. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
152. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd Edition. New York: Wiley, 1981:217-34.
153. Garber AJ. Metformin and vascular protection: a diabetologists view. Diabetes Metabolism 2003;4 pt 2:6S113-6.
154. Garrow JS. Obesity and related diseases. New York: Churchill Livingstone, 1988.
155. Grant PJ. Benefitial effects of metformin on haemostasis and vascular function in man. Diabetes Metabolism 2003;4 Pt 2:6S44-52.
156. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17(10):1100-9.
157. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
158. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
159. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999;22:33-7.
160. Kilpatrick ES. UK's diagnostic criteria for diabetes are different from US's. BMJ 1999;319(7214):922.
161. Mamputu JC, Wiernsperger NF, Renier. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metabolism 2003;4 Pt 2:6S71-6.
162. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. British Medical Journal 2000;320:1720-3.
163. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl):789-830.
164. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Medical Association Journal 1998;159 (8 Suppl):S1-29.
165. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. The Lancet 1999;354:1896-900.
166. Moher, D, Schulz, KF, Altman, DG, for the CONSORT group. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Journal of the American Medical Association 2001;285:1987-91.
167. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. The Lancet 1998;352(9131):832-3.
168. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
169. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. Journal of American Medical Association 1999;282(8):786-90.
170. Richter B, Ebrahim S, BergerhoffK, Clar C, de Leiva A, Manning P, et al. Aditional information: Diabetes mellitus. Metabolic and Endocrine Disorders Group. About the Cochrane Collaboration (Collaborative Review Groups (CRGs)). 2004.
171. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Cochrane Review). The Cochrane Library 2003, Issue 1.
172. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical Evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
173. Shaughnessy AF, Slawson DC. What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ 2003;327:266-9.
174. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes-UKPDS 33. Lancet 1998;352:837-52.
175. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854-65.
176. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-13.
177. WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva: World Health Organization, 1980.
178. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
179. Yki-Järvinen H, Ryysy L, Nikkilö K, Tulokas T, Vanamo R, Heikkilö M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomised controlled trial. Annals of Internal Medicine 1999;130:389-96.